Physician profile

Katie E Wilson

Psychiatry · Saint Louis, MO

NPI 1225185119

$1,334.14

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$76.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Neos Therapeutics, LP $367.48 2019-2024 Adzenys Xr-Odt
Ironshore Pharmaceuticals INC. $267.13 2019-2020
Tris Pharma INC $180.36 2019-2020
Janssen Pharmaceuticals, INC $171.06 2019
Rhodes Pharmaceuticals L.P. $145.31 2019
Sunovion Pharmaceuticals INC. $82.53 2019
Vertical Pharmaceuticals, LLC $37.78 2019
Shire North American Group INC $36.33 2019
Takeda Pharmaceuticals U.S.A., INC. $31.73 2020
Adlon Therapeutics L.P. $14.43 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Katie E Wilson

$1,334.14

in general payments reported 2019-2025

Years
2019-2024
Top company
Neos Therapeutics, LP

https://glasscript.com/doctor/1195167/katie-e-wilson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.